Skip to content

Assessment of Elderly Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Multi-domain Assessment and Quality of Life in Patients Older Than 60 Years Receiving an Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04375579
Acronym
ELDERGRAF
Enrollment
205
Registered
2020-05-05
Start date
2020-07-03
Completion date
2024-10-17
Last updated
2024-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stem Cell Transplant

Brief summary

Patients older than 60 years are more and more transplanted. Comprehensive geriatric assessment (CGA) have been developed and are currently used in patients with cancer, it has been correlated with the prognosis. There is still few data in transplanted patients and the aim of this study is to assess these patients before and after transplantation in order to monitor their general health and quality of life (QOF) and correlate them to the prognostic.

Interventions

Questionnaires on nutritional status, autonomy and quality of life

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 60 years or more at time of transplantation * Patient receiving a hematopoietic stem cell allograft for myeloid hemopathy (myeloid acute leukemia, myelodysplastic syndrome, Myeloproliferative neoplasm) or for an Acute lymphoblastic leukemia * No opposition to participate

Exclusion criteria

* Patient opposed to the protocol * Vulnerable patients protected by curatorship or administrative supervision * Patients not covered by a social security scheme

Design outcomes

Primary

MeasureTime frame
Overall survivalat one year post allogeneic hematopoietic stem cell transplantation

Secondary

MeasureTime frameDescription
Morbidity Indexat one year
Survival without disease and chronic graft-versus-host diseaseat one year post allogeneic hematopoietic stem cell transplantation
Proportion of patient with Viral Reactivationat one yearReactivation of cytomegalovirus (CMV) or Epstein-Barr virus (EBV) virus
Acute graft-versus-host diseaseat 100 days
Chronic graft-versus-host diseaseat 1 year
Incidence of relapseat two years
Walk testat day 100Walk tests measure the functional level of patients suffering from a wide range of cardiac, respiratory, neurological, and musculoskeletal conditions.
Nutritional scoreat day 100Nutrional score will be assessed using the simple evaluation of food intake (SEFI scale). The minimum value is 0 and the maximum is 10. The highest score mean that the patient's food intake are the same as usual.
Karnofsky indexat day 100The Karnofsky index is a synthetic indicator of the overall health status measuring, on a scale from 0 (death) to 100 (full health)
Overall survivalat two years post allogeneic hematopoietic stem cell transplantation
Evaluation of Quality of lifeat one yearQuality of life evaluated using questionnaire European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30- v3). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for a functional scale represents a high/healthy level of functioning. A high score for the global health status/ QoL represents a high QoL and a high score for a symptom scale/item represents a high level of symptomatology/problems. EORTC QLQ-C30 Scoring Manual. Fayers PM et al. on behalf of the EORTC Quality of Life Group. EORTC, 2001. ISBN: 2-9300.
Length of hospitalisation initiallyat two years
Length of hospitalisation during the first year after graftUp to one year
Questionnaire completion rateAt 2 years
Length of pre-grafting visitAt 2 years
Length of D100 visitAt 2 years
Length of 1year visitAt 2 years
Length of 2 years visitAt 2 years
Evaluation of autonomyat one yearAutonomy will be evaluated using ADL and IADL score. Instrumental activities of daily living - global score range from 0 to 4.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026